TARSUS PHARMACEUTICALS, INC. (TARS) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $6.00K; Additional Paid in CapitalUSD $799.43M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-557.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $6.00K; Additional Paid in CapitalUSD $782.84M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-298.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $6.00K; Additional Paid in CapitalUSD $769.67M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $381.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $6.00K; Additional Paid in CapitalUSD $753.04M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $289.00K.
TARSUS PHARMACEUTICALS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $6.00K | $799.43M | $-557.00K | $-452.15M | $346.73M | 3 month · $13.29M | (m) | (m) |
| 2026-03-31 | $0.00 | $6.00K | $782.84M | $-298.00K | $-433.60M | $348.95M | 3 month · $11.97M | (m) | (m) |
| 2025-12-31 | $0.00 | $6.00K | $769.67M | $381.00K | $-426.63M | $343.43M | 12 month · $41.72M | (m) | (m) |
| 2025-09-30 | $0.00 | $6.00K | $753.04M | $289.00K | $-418.25M | $335.08M | 3 month · $12.24M | (m) | (m) |
| 2025-06-30 | $0.00 | $6.00K | $738.24M | $39.00K | $-405.67M | $332.61M | 3 month · $8.23M | (m) | (m) |
| 2025-03-31 | $0.00 | $6.00K | $727.70M | $85.00K | $-385.33M | $342.46M | 3 month · $6.93M | (m) | (m) |
| 2024-12-31 | $0.00 | $6.00K | $584.56M | $179.00K | $-360.21M | $224.53M | 12 month · $27.82M | 12 month · $9.37M | (m) |
| 2024-09-30 | $0.00 | $6.00K | $574.23M | $346.00K | $-337.10M | $237.48M | 3 month · $7.42M | (m) | (m) |
| 2024-06-30 | $0.00 | $6.00K | $566.09M | $-176.00K | $-313.68M | $252.25M | 3 month · $7.48M | (m) | (m) |
| 2024-03-31 | $0.00 | $6.00K | $555.65M | $-63.00K | $-280.39M | $275.21M | 3 month · $5.52M | 3 month · $9.37M | (m) |
| 2023-12-31 | $0.00 | $5.00K | $441.64M | $-2.00K | $-244.66M | $196.99M | 12 month · $19.83M | (m) | (m) |
| 2023-09-30 | $0.00 | $5.00K | $416.42M | $-8.00K | $-202.75M | $213.66M | 3 month · $5.25M | (m) | (m) |
| 2023-06-30 | $0.00 | $5.00K | $311.35M | $-23.00K | $-163.61M | $147.73M | 3 month · $5.19M | (m) | (m) |
| 2023-03-31 | $0.00 | $5.00K | $305.65M | $-70.00K | $-132.18M | $173.40M | 3 month · $3.91M | (m) | (m) |
| 2022-12-31 | $0.00 | $5.00K | $301.73M | $-74.00K | $-108.76M | $192.90M | 12 month · $13.46M | (m) | (m) |
| 2022-09-30 | $0.00 | $5.00K | $297.80M | $-10.00K | $-95.16M | $202.63M | 3 month · $3.58M | (m) | 3 month · $34.00K |
| 2022-06-30 | $0.00 | $5.00K | $294.15M | (m) | $-72.65M | $221.50M | 3 month · $3.53M | (m) | (m) |
| 2022-03-31 | $0.00 | $4.00K | $216.10M | (m) | $-66.91M | $149.20M | 3 month · $2.67M | (m) | (m) |
| 2021-12-31 | $0.00 | $4.00K | $213.40M | $0.00 | $-46.67M | $166.73M | 12 month · $8.46M | (m) | (m) |
| 2021-09-30 | $0.00 | $4.00K | $210.96M | (m) | $-31.82M | $179.14M | 3 month · $2.12M | (m) | (m) |
| 2021-06-30 | $0.00 | $4.00K | $208.59M | (m) | $-16.12M | $192.47M | 3 month · $2.79M | (m) | (m) |
| 2021-03-31 | $0.00 | $4.00K | $205.70M | (m) | $-22.47M | $183.23M | 3 month · $1.36M | (m) | (m) |
| 2020-12-31 | $0.00 | $4.00K | $198.82M | (m) | $-32.84M | $165.98M | 12 month · $839.00K | (m) | (m) |
| 2020-09-30 | (m) | $2.00K | $3.55M | (m) | $-21.38M | $-17.83M | 3 month · $223.00K | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | $-11.04M | 3 month · $173.00K | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | $-7.96M | 3 month · $4.00K | (m) | (m) |
| 2019-12-31 | $0.00 | $2.00K | $27.00K | (m) | $-6.03M | $-6.00M | 12 month · $18.00K | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | $-4.60M | 3 month · $5.00K | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | $-3.92M | 3 month · $5.00K | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | $-3.10M | 3 month · $4.00K | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | (m) | $-1.35M | 12 month · $9.00K | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | $-44.00K | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |